...13% and 8% of DMD patients, respectively.‘Real-time’ review for tepotinib in NSCLC FDA will review tepotinib...
...hydrocarbon receptorc-MET (MET; HGFR) - c-Met receptor tyrosine kinase BC Staff benvitimod, tapinarof (DMVT-505, GSK2894512, WBI-1001) Tepmetko (tepotinib, MSC2156119J) asciminib...

...is the first c-MET inhibitor for the patient subset to gain FDA approval, but Tempetko tepotinib...

...Merck KGaA’s tepotinib for NSCLC Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved tepotinib...
...receptor tyrosine kinase LpxC - Bacterial UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase PDE-4 - Phosphodiesterase-4 Hongjiang Li, Staff Writer tepotinib (MSC2156119J) JZP-258 Pear...

...and pralsetinib from Blueprint Medicines Co. are both designed for RET fusion-positive tumors; Merck KGaA’s tepotinib...
...KGaA reported an ORR of 50% across all treatment lines in c-Met positive patients for tepotinib...
...to file an NDA this year for capmatinib, and Merck is planning an NDA for tepotinib...

...tepotinib data Also reporting c-MET inhibitor data Monday at ASCO, Merck KGaA (Xetra:MRK) said tepotinib (MSC2156119J...
...registrational” trial, but did not disclose regulatory plans for tepotinib. Brian Moy, Assistant Editor capmatinib (INC280, incb28060) tepotinib (MSC2156119J) Aadi...

...Merck KGaA (Xetra:MRK) said 500 mg once-daily tepotinib (MSC2167119J) led to a partial response rate of...
...therapy. Tepotinib is a small molecule c-MET inhibitor. Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: Tepotinib (MSC2156119J...
...safety, quality of life and pharmacokinetics Status: Updated Phase II data Milestone: NA Jaime De Leon tepotinib (MSC2156119J) American...

...Merck KGaA (Xetra:MRK) said once-daily oral tepotinib (MSC2156119J) as first- and second-line treatment each met the...
...Tepotinib is a small molecule c-MET inhibitor. Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: Tepotinib (MSC2156119J...
...and biological response rate Status: Additional Phase Ib/II data Milestone: Additional data (2018) Jaime De Leon tepotinib (MSC2156119J) American...

...enrolled patients who were anti-PD-1/PD-L1 naïve. Merck KGaA presented data from Phase II trials of tepotinib...
...metastatic NSCLC patients harboring c-MET exon 14-skipping mutations, who had received previous treatment with chemotherapy, tepotinib...
...in PD-1 naïve patients. Luciano Rossetti, head of global R&D at Merck KGaA, said the tepotinib...

...’s Phase III candidate savolitinib and the Phase II compounds capmatinib from Novartis AG and tepotinib...
...Octimet is currently investigating whether the three competitors bind OCT2. Merck spokesperson Brenda Mulligan said tepotinib...

...oral tepotinib (MSC2156119J) led to 2 unconfirmed partial responses and 1 case of stable disease. Tepotinib...
...pharmacokinetics. Tepotinib is a small molecule c-MET inhibitor. Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: Tepotinib (MSC2156119J...
...survival (OS), safety, quality of life (QOL) and pharmacokinetics Status: Phase II data Milestone: NA Julian Zhu MSC2156119J tepotinib American...